JP6664219B2 - 幹細胞増強治療法 - Google Patents
幹細胞増強治療法 Download PDFInfo
- Publication number
- JP6664219B2 JP6664219B2 JP2015527590A JP2015527590A JP6664219B2 JP 6664219 B2 JP6664219 B2 JP 6664219B2 JP 2015527590 A JP2015527590 A JP 2015527590A JP 2015527590 A JP2015527590 A JP 2015527590A JP 6664219 B2 JP6664219 B2 JP 6664219B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- cells
- antibodies
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims description 170
- 238000002560 therapeutic procedure Methods 0.000 title description 2
- 230000003416 augmentation Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims description 155
- 201000011510 cancer Diseases 0.000 claims description 125
- 210000004027 cell Anatomy 0.000 claims description 116
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 93
- 238000000034 method Methods 0.000 claims description 33
- 230000010261 cell growth Effects 0.000 claims description 26
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 230000000235 effect on cancer Effects 0.000 claims 1
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 60
- 102100034256 Mucin-1 Human genes 0.000 description 60
- 125000003275 alpha amino acid group Chemical group 0.000 description 49
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 48
- 238000011282 treatment Methods 0.000 description 36
- 150000001413 amino acids Chemical class 0.000 description 21
- 230000012010 growth Effects 0.000 description 21
- 210000000601 blood cell Anatomy 0.000 description 17
- 241000699670 Mus sp. Species 0.000 description 16
- 230000000694 effects Effects 0.000 description 12
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 11
- 208000026310 Breast neoplasm Diseases 0.000 description 10
- 206010060862 Prostate cancer Diseases 0.000 description 10
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 10
- 206010006187 Breast cancer Diseases 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 8
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 8
- 101000979629 Homo sapiens Nucleoside diphosphate kinase A Proteins 0.000 description 8
- 102100023252 Nucleoside diphosphate kinase A Human genes 0.000 description 8
- 210000001185 bone marrow Anatomy 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 7
- 239000000539 dimer Substances 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 108010074604 Epoetin Alfa Proteins 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 238000002823 phage display Methods 0.000 description 6
- 208000023958 prostate neoplasm Diseases 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 238000011579 SCID mouse model Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003173 antianemic agent Substances 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 230000005907 cancer growth Effects 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 210000001671 embryonic stem cell Anatomy 0.000 description 5
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000004614 tumor growth Effects 0.000 description 5
- 108091028684 Mir-145 Proteins 0.000 description 4
- 208000007502 anemia Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000006471 dimerization reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940089118 epogen Drugs 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 3
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 102000009465 Growth Factor Receptors Human genes 0.000 description 3
- 108010009202 Growth Factor Receptors Proteins 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 238000010322 bone marrow transplantation Methods 0.000 description 3
- 208000020832 chronic kidney disease Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000011476 stem cell transplantation Methods 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108010019673 Darbepoetin alfa Proteins 0.000 description 2
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 229940115115 aranesp Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940087875 leukine Drugs 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940029359 procrit Drugs 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 108010038379 sargramostim Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 102400000108 N-terminal peptide Human genes 0.000 description 1
- 101800000597 N-terminal peptide Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000003732 agents acting on the eye Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 1
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000000447 dimerizing effect Effects 0.000 description 1
- 210000000267 erythroid cell Anatomy 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 229940125702 ophthalmic agent Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 1
- 229960002169 plerixafor Drugs 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261683155P | 2012-08-14 | 2012-08-14 | |
| US61/683,155 | 2012-08-14 | ||
| US201261684654P | 2012-08-17 | 2012-08-17 | |
| US61/684,654 | 2012-08-17 | ||
| US201261693712P | 2012-08-27 | 2012-08-27 | |
| US61/693,712 | 2012-08-27 | ||
| PCT/US2012/060684 WO2013059373A2 (en) | 2011-10-17 | 2012-10-17 | Media for stem cell proliferation and induction |
| USPCT/US2012/060684 | 2012-10-17 | ||
| PCT/US2013/025981 WO2013123084A1 (en) | 2012-02-13 | 2013-02-13 | Method for detecting circulating fetal cells |
| USPCT/US2013/025981 | 2013-02-13 | ||
| US201361837560P | 2013-06-20 | 2013-06-20 | |
| US61/837,560 | 2013-06-20 | ||
| PCT/US2013/055015 WO2014028668A2 (en) | 2012-08-14 | 2013-08-14 | Stem cell enhancing therapeutics |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017238427A Division JP6757712B2 (ja) | 2012-08-14 | 2017-12-13 | 幹細胞増強治療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015526446A JP2015526446A (ja) | 2015-09-10 |
| JP2015526446A5 JP2015526446A5 (enExample) | 2016-10-06 |
| JP6664219B2 true JP6664219B2 (ja) | 2020-03-13 |
Family
ID=50101604
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015527590A Active JP6664219B2 (ja) | 2012-08-14 | 2013-08-14 | 幹細胞増強治療法 |
| JP2017238427A Active JP6757712B2 (ja) | 2012-08-14 | 2017-12-13 | 幹細胞増強治療法 |
| JP2020037396A Pending JP2020109101A (ja) | 2012-08-14 | 2020-03-05 | 幹細胞増強治療法 |
| JP2021181985A Pending JP2022025136A (ja) | 2012-08-14 | 2021-11-08 | 幹細胞増強治療法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017238427A Active JP6757712B2 (ja) | 2012-08-14 | 2017-12-13 | 幹細胞増強治療法 |
| JP2020037396A Pending JP2020109101A (ja) | 2012-08-14 | 2020-03-05 | 幹細胞増強治療法 |
| JP2021181985A Pending JP2022025136A (ja) | 2012-08-14 | 2021-11-08 | 幹細胞増強治療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US9932407B2 (enExample) |
| EP (1) | EP2885000A4 (enExample) |
| JP (4) | JP6664219B2 (enExample) |
| CN (3) | CN104717980A (enExample) |
| AU (2) | AU2013302620B2 (enExample) |
| CA (1) | CA2882222A1 (enExample) |
| IL (1) | IL237228B (enExample) |
| WO (1) | WO2014028668A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102239182B (zh) * | 2008-10-06 | 2014-07-09 | 米纳瓦生物技术公司 | Muc1*抗体 |
| EP4050103A1 (en) | 2014-04-07 | 2022-08-31 | Minerva Biotechnologies Corporation | Anti-nme antibody |
| JP6895890B2 (ja) * | 2015-02-10 | 2021-06-30 | ミネルバ バイオテクノロジーズ コーポレーション | ヒト化抗ｍｕｃ１＊ 抗体 |
| JP7197078B2 (ja) * | 2016-04-08 | 2022-12-27 | ジィールバイオ，インコーポレーテッド | プレクチン１結合性抗体およびその使用 |
| US20210107989A1 (en) * | 2017-04-04 | 2021-04-15 | Corvus Pharmaceuticals, Inc. | Methods for treating cd73hi tumors |
| CN112105380A (zh) * | 2017-10-11 | 2020-12-18 | 埃缇健康公司D/B/A泽尔拜尔 | 网蛋白-1结合抗体和其用途 |
| CA3121624A1 (en) | 2018-12-06 | 2020-06-11 | Arthrosi Therapeutics, Inc. | Methods for treating or preventing gout or hyperuricemia |
| CN120484122A (zh) * | 2019-01-11 | 2025-08-15 | 米纳瓦生物技术公司 | 抗可变muc1*抗体及其用途 |
| CN113727602B (zh) | 2019-02-04 | 2023-10-03 | 米纳瓦生物技术公司 | 抗nme抗体及治疗癌症或癌症转移的方法 |
| IL298780A (en) | 2020-06-08 | 2023-02-01 | Minerva Biotechnologies Corp | Anti-nme antibody and method of treating cancer or cancer metastasis |
| CN116075318A (zh) | 2020-06-26 | 2023-05-05 | 米纳瓦生物技术公司 | 抗nme抗体及治疗癌症或癌症转移的方法 |
| WO2023201234A2 (en) | 2022-04-12 | 2023-10-19 | Minerva Biotechnologies Corporation | Anti-variable muc1* antibodies and uses thereof |
| US20240261406A1 (en) | 2023-02-02 | 2024-08-08 | Minerva Biotechnologies Corporation | Chimeric antigen receptor compositions and methods for treating muc1* diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0505566A1 (en) * | 1989-12-15 | 1992-09-30 | Takeda Chemical Industries, Ltd. | Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics |
| US5342947A (en) * | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
| JP2005508839A (ja) * | 2001-03-29 | 2005-04-07 | ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッド | ペプチドおよびｍｕｃ１タンパク質に対する抗体 |
| EP2329822A1 (en) * | 2001-09-05 | 2011-06-08 | Minerva Biotechnologies Corporation | Compositions and methods of treatment of cancer |
| JP2006504630A (ja) * | 2002-04-22 | 2006-02-09 | ダイアックス コーポレイション | ムチンポリペプチドに特異的な抗体 |
| EP1536814A4 (en) * | 2002-07-03 | 2006-02-15 | Immunogen Inc | ANTIBODIES AGAINST MUC1 AND MUC16 NOT RELEASED AND USES THEREOF |
| EP2526957A3 (en) | 2005-03-30 | 2013-02-20 | Minerva Biotechnologies Corporation | Proliferation of MUC1 expressing cells |
| US7825092B2 (en) * | 2006-08-08 | 2010-11-02 | University Of South Florida | Dendroaspis natriuretic peptide for treatment of cancer |
| US20090075926A1 (en) | 2006-12-06 | 2009-03-19 | Bamdad Cynthia C | Method for identifying and manipulating cells |
| US20100104626A1 (en) * | 2007-02-16 | 2010-04-29 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
| CN102239182B (zh) * | 2008-10-06 | 2014-07-09 | 米纳瓦生物技术公司 | Muc1*抗体 |
| KR20140101876A (ko) * | 2008-10-09 | 2014-08-20 | 미네르바 바이오테크놀로지 코포레이션 | 세포내에서 다능성을 유도하기 위한 방법 |
| CN102264765B (zh) * | 2008-10-28 | 2016-01-20 | 盐野义制药株式会社 | 抗muc1抗体 |
| US8628959B2 (en) * | 2009-05-23 | 2014-01-14 | Incube Labs, Llc | Methods for cancer treatment using stem cells |
| EA026732B1 (ru) * | 2009-06-11 | 2017-05-31 | Минерва Байотекнолоджиз Корпорейшн | Способы культивирования стволовых клеток и клеток-предшественников |
| US20120156246A1 (en) * | 2010-06-16 | 2012-06-21 | Bamdad Cynthia C | Reprogramming cancer cells |
-
2013
- 2013-08-14 CN CN201380053708.7A patent/CN104717980A/zh active Pending
- 2013-08-14 JP JP2015527590A patent/JP6664219B2/ja active Active
- 2013-08-14 AU AU2013302620A patent/AU2013302620B2/en active Active
- 2013-08-14 CA CA2882222A patent/CA2882222A1/en active Pending
- 2013-08-14 CN CN202010192670.3A patent/CN111388664A/zh active Pending
- 2013-08-14 CN CN201810110588.4A patent/CN108175856B/zh active Active
- 2013-08-14 EP EP13829213.1A patent/EP2885000A4/en active Pending
- 2013-08-14 WO PCT/US2013/055015 patent/WO2014028668A2/en not_active Ceased
-
2015
- 2015-02-13 US US14/622,677 patent/US9932407B2/en active Active
- 2015-02-15 IL IL237228A patent/IL237228B/en active IP Right Grant
-
2016
- 2016-12-28 US US15/392,858 patent/US20170121406A1/en not_active Abandoned
-
2017
- 2017-12-13 JP JP2017238427A patent/JP6757712B2/ja active Active
-
2018
- 2018-08-24 AU AU2018220126A patent/AU2018220126B2/en active Active
-
2020
- 2020-03-05 JP JP2020037396A patent/JP2020109101A/ja active Pending
-
2021
- 2021-11-08 JP JP2021181985A patent/JP2022025136A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL237228A0 (en) | 2015-04-30 |
| CN111388664A (zh) | 2020-07-10 |
| AU2018220126A1 (en) | 2018-09-13 |
| CN104717980A (zh) | 2015-06-17 |
| US20170121406A1 (en) | 2017-05-04 |
| AU2013302620A1 (en) | 2015-04-02 |
| EP2885000A2 (en) | 2015-06-24 |
| JP2015526446A (ja) | 2015-09-10 |
| CN108175856A (zh) | 2018-06-19 |
| JP2020109101A (ja) | 2020-07-16 |
| WO2014028668A3 (en) | 2014-05-01 |
| JP2018070640A (ja) | 2018-05-10 |
| IL237228B (en) | 2021-03-25 |
| JP6757712B2 (ja) | 2020-09-23 |
| CA2882222A1 (en) | 2014-02-20 |
| EP2885000A4 (en) | 2015-12-23 |
| JP2022025136A (ja) | 2022-02-09 |
| CN108175856B (zh) | 2024-01-26 |
| US9932407B2 (en) | 2018-04-03 |
| AU2013302620B2 (en) | 2018-08-02 |
| US20150299334A1 (en) | 2015-10-22 |
| WO2014028668A2 (en) | 2014-02-20 |
| AU2018220126B2 (en) | 2020-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6664219B2 (ja) | 幹細胞増強治療法 | |
| JP6823094B2 (ja) | Ｒｏｒ１癌の治療および転移の阻害に使用するための抗体およびワクチン | |
| JP7011574B2 (ja) | Ｆｌｔ３及びｃｄ３に対する抗体構築物 | |
| CN104136037B (zh) | 高亲和力SIRP‑α试剂 | |
| RU2013108054A (ru) | Антитела против а2 тенасцина с и способы их применения | |
| TW201806620A (zh) | 藉由拮抗ｉｌ-６受體抑制腫瘤生長之方法 | |
| CA2830908C (en) | Methods and compositions for improving antiangiogenic therapy with anti-integrins | |
| JP2013538813A (ja) | 抗ｖｅｇｆｒ−３抗体組成物 | |
| JP2022028075A (ja) | 免疫寛容を誘導する抗体、誘導されたリンパ球、また誘導されたリンパ球を用いる細胞治療剤治療法 | |
| US20240254219A1 (en) | Novel wnt agonist antibodies and therapeutic uses thereof | |
| US20240368259A1 (en) | Antibodies against lefty proteins | |
| JP2025540215A (ja) | Ｃｄ４７遮断剤と抗ｂｃｍａ／抗ｃｄ３二重特異性抗体との組合せ療法 | |
| TW202430214A (zh) | Cd47阻斷劑及抗bcma/抗cd3雙特異性抗體之組合療法 | |
| JP2015199725A (ja) | 中和活性を有する抗ｌｒ１１モノクローナル抗体、及びそれを含有してなる医薬 | |
| HK40005045B (zh) | 用於治疗ror1癌症并抑制转移的抗体和疫苗 | |
| HK40005045A (en) | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis | |
| JP2021504492A (ja) | 癌治療のための組成物および方法 | |
| JP2015199724A (ja) | 中和活性を有する抗ｌｒ１１モノクローナル抗体、及びそれを含有してなる医薬 | |
| HK1191378A1 (zh) | 针对人前列腺素e2受体ep4的抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160815 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160815 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170613 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170904 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171113 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180531 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180828 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180829 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190115 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190409 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190610 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190711 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190801 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191202 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20191211 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20200123 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200218 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6664219 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: R3D02 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |